Format

Send to

Choose Destination
Drug Des Devel Ther. 2019 Jan 22;13:435-445. doi: 10.2147/DDDT.S186352. eCollection 2019.

MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689.

Author information

1
Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, P.R. China, shaoglzlyy@163.com.
2
Department of Integration of Traditional Chinese and Western Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, P.R. China, zhangyj770323@163.com.

Abstract

Background:

Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality worldwide, however, the prognosis for HCC remains unsatisfactory. This study aimed to explore the role of miR-339-5p in HCC.

Methods:

We first used quantitative real-time PCR to examine the level of miR-339-5p in HCC tissues. Then we further adopted Western blotting assay, CCK8, cell invasion assays, apoptosis detection assay, and luciferase assay to analyze how it mediate the development of HCC.

Results:

We found that miR-339 is significantly decreased in primary HCC tissues. Overexpression of miR-339 in HCC cells remarkably suppressed proliferation and invasion and induced apoptosis. However, silencing miR-339 in HCC cells promoted proliferation and invasion, and reduced apoptosis. Moreover, we demonstrated that ZNF689 is a target of miR-339 and there is a negative correlation between miR-339 and ZNF689 expression in the HCC tissues. Overexpression of ZNF689 in miR-339-overexpressing HCC cells partially antagonized the inhibitory effects of miR-339.

Conclusion:

Our study revealed that miR-339 inhibits HCC growth through targeting oncoprotein ZNF689 and restoration of miR-339 might be feasible therapeutic strategy for HCC treatment.

KEYWORDS:

HCC; ZNF689; miR-339-5p; proliferation; treatment

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center